ADVIA Centaur XP Immunoassay SystemHow does your lab meet varied testing demands?
Can your lab handle both routine and specialized testing without sacrificing efficiency? Can you maintain speed and accuracy for an increasingly diverse patient population? The high-performance ADVIA Centaur® XP system has more onboard reagents and dedicated STAT capabilities to maximize productivity, regardless of volume or types of tests. Always ready, continuous operation without interruption.
- High throughput, up to 240 tests/hour
- Intuitive software for ease of operation
- STAT port guarantees priority sampling at any time
- Data archive reduces administrative tasks
- Extensive menu with 30 onboard reagents
- Increase productivity by connecting to Siemens' Aptio™ Automation, ADVIA® Automation, StreamLAB® Automation or VersaCell® Solutions
Features & Benefits
Comprehensive Menu
- Comprehensive diagnostic testing covers screening, diagnosis, risk assessment and monitoring
- 30 onboard reagents maximize test capacity
Powerful Productivity
- High throughput, up to 240 tests per hour, to keep pace with peak workload times
- High-resolution touch screen for easy interaction
- Expanded ancillary reagent and fluid capacity
- Data archive feature reduces time for administrative tasks
- Universal sample rack design eliminates manual tasks
Excellent Patient Care
- STAT port guarantees priority sampling at any time
- Disposable pipette tips eliminate sample-to-sample carryover
- Automatic dilution, repeat and reflex testing
- Smart Algorithm Software automatically repeats and confirms reactive testing
Superior Service
- 360º status light displays system information visible from all points
- User interface adjusts for customized ergonomics
- No daily startup with automated maintenance features
- New instrument sensors enhance remote diagnostic functions
Flexible Solutions
- Connectivity to Aptio™ Automation, ADVIA® Automation, StreamLAB® Automation and VersaCell® Solutions
- Siemens Remote Service (SRS) proactively maintains Siemens' systems
Assays
Anemia
Active B12
Ferritin
Folate
RBC Folate
Vitamin B12
Autoimmune
Anti-CCP
Bone Metabolism
Intact PTH
Vitamin D Total
Cardiac
BNP
CKMB
High-Sensitivity Troponin I (TNIH)
Myoglobin
Tnl-Ultra™
Diabetes
C-Peptide
Insulin
Hepatitis
Anti-HBs-2
HAV IgM
HAV Total
HBc IgM
HBc Total
HBeAg
HBsAg Confirmatory
HBs AgII
HCV**
HIV
HIV 1/0/2 Enhanced (EHIV)§
HIV Combo§
Immunosuppressant Drugs
Cyclosporine
Everolimus*
Tacrolimus*
Inflammation
IgE, Total
Metabolic
Cortisol
Homocysteine
Oncology
AFP
BR 27.29
CA 125II‡
CA 15-3
CA 19-9
Calcitonin
CEA
Complexed PSA
PSA
Serum HER-2/neu
Reproductive Endocrinology
AFP
Anti-Müllerian Hormone*
DHEAS
Enhanced Estradiol
Free βhCG‡‡
FSH
hCG
LH
PAPP-A‡‡
PIGF*
Progesterone
Prolactin
sFLT-1*
SHBG
Testosterone
Special ID
EBV-EBNA IgG*
EBV-VCA IgG*
EBV-VCA IgM*
Syphilis
Zika IgM††
Therapeutic Drug Monitoring
Carbamazepine
Digitoxin
Digoxin
Gentamicin
Phenobarbital
Phenytoin
Theophylline
Valproic Acid
Vancomycin
Thyroid
Anti-TG
Anti-TPO
Free T3
Free T4
T Uptake
Total T3
Total T4
TSH3-Ultra
TSH
ToRCH
CMV IgG
CMV IgM*
Herpes I
Herpes II
Rubella IgG
Rubella IgM
Toxoplasma IgG
Toxoplasma IgM
Technical Specifications
Did this information help you?
* Under development. Not available for sale.
† Not available for sale in the U.S.
‡ CA 125II is a trademark of Fujirebio Diagnostics, Inc.
§ Assay developed, manufactured, and sold by Siemens Healthcare Diagnostics Inc. for Ortho Clinical Diagnostics, Inc. and Grifols Diagnostic Solutions Inc.
** For outside of the U.S. only, assay developed, manufactured, and sold by Siemens Healthcare Diagnostics Inc. for Ortho Clinical Diagnostics, Inc. and Grifols Diagnostic Solutions Inc.
†† The ADVIA Centaur Zika Test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for the diagnosis for Zika virus infection and not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner
‡‡ For Research Use Only in the U.S. Not for use in clinical or diagnostic procedures in the U.S.